{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:07Z","timestamp":1781179087895,"version":"3.54.1"},"reference-count":12,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":141,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Recurrent metastatic head and neck squamous cell carcinoma (HNSCC) patients carry a poor prognosis and have limited therapeutic options. In the randomized phase-3 trial CheckMate 141, nivolumab showed benefit in overall survival (OS) with manageable toxicity. Nivolumab is available for clinical practice since 2017 in India. The aim of this study is to evaluate the efficacy and safety of nivolumab in real-world settings in India.<\/jats:p>\n                  <jats:p>Materials and Methods This is a retrospective, single-center study on the use of nivolumab with advanced or metastatic HNSCC in India. Eligible patients had histologically confirmed, recurrent squamous cell carcinoma of the head and neck (including metastatic disease) of the oral cavity, pharynx, or larynx that was not amenable to curative treatment, tumor progression, or recurrence after the administration of platinum-containing chemotherapy administered as adjuvant therapy or in the context of primary or recurrent disease. We assessed demographics, safety (the Common Terminology Criteria for Adverse Events Version 4.0), response evaluation (the Response Evaluation Criteria in Solid Tumors Version 1.1), progression-free survival (PFS), and OS.<\/jats:p>\n                  <jats:p>Results Among patients with platinum-refractory, recurrent HNSCC, and treatment with nivolumab resulted in median PFS of 2 months and median OS of 5 months, which is inferior to what was seen in CheckMate 141. Fifteen of 20 patients (75%) had progressive disease, 3 (15%) showed a partial response, and 2 (10%) had stable disease.<\/jats:p>\n                  <jats:p>Conclusion Nivolumab was well tolerated in our study with fewer toxic effects, and an inferior median survival was reached as compared with CheckMate 141 in platinum refractory, recurrent HNSCC patients treated with nivolumab because 90% of patients in our study received nivolumab as second-line therapy after progression. Our study encourages the use of nivolumab in this population.<\/jats:p>","DOI":"10.1055\/s-0041-1729443","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T18:45:04Z","timestamp":1629485104000},"page":"72-75","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer"],"prefix":"10.25259","volume":"10","author":[{"given":"Waseem","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Goel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga R.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Promila","family":"Pankaj","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devashish","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik P.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Popli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Max Super Speciality Hospital, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1368-8375(99)00070-6","article-title":"Comparison of cancers of the oral cavity and pharynx worldwide: etiological clues","volume":"36","author":"S Franceschi","year":"2000","journal-title":"Oral Oncol"},{"issue":"01","key":"ref3","first-page":"108","article-title":"Trends of head and neck cancers in urban and rural India","volume":"7","author":"J K Elango","year":"2006","journal-title":"Asian Pac J Cancer Prev"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02907731","article-title":"Prevalence of head and neck cancers in the north east-An institutional study","volume":"58","author":"A Bhattacharjee","year":"2006","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0019-509X.16698","article-title":"Trends of prevalence and pathological spectrum of head and neck cancers in North India","volume":"42","author":"R Mehrotra","year":"2005","journal-title":"Indian J Cancer"},{"issue":"10","key":"ref6","first-page":"5499","article-title":"Survival after distant metastasis in head and neck cancer","volume":"35","author":"S Wiegand","year":"2015","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"A Argiris","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers10110421","article-title":"Persistent head and neck cancer following first-line treatment","volume":"10","author":"T B Steinbichler","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"J B Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"ref10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"R L Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"ref11","first-page":"156","article-title":"KEYNOTE-040: a phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer","volume":"33","author":"E E Cohen","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"B Burtness","year":"2019","journal-title":"Lancet"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1729443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:23Z","timestamp":1781176343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/real-world-experience-of-immunotherapy-from-india-in-recurrent-squamous-cell-carcinoma-of-head-and-neck-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":12,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1729443","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}